Sentinel node biopsy: An in depth appraisal

Critical Reviews in Oncology/Hematology

Volumn 44, Issue 1, 2002, Pages 45-70

  Strickland, Andrew H ^a   Beechey Newman, Nicolas ^b   Steer, Christopher B ^b   Harper, Peter G ^b  

^a MONASH MEDICAL CENTRE   (Australia)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

Adjuvant chemotherapy; Breast cancer; Internal mammary nodes; Lymphoscintigraphy; Micrometastases; Sentinel lymph node

Indexed keywords

ANTIMONY TECHNETIUM SULFIDE TC 99M; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MONOCLONAL ANTIBODY; TECHNETIUM SULFUR COLLOID TC 99M;

ADJUVANT CHEMOTHERAPY; AXILLARY LYMPH NODE; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; METASTASIS; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW; RISK; SENTINEL LYMPH NODE BIOPSY; ULTRASOUND; BREAST TUMOR; DIAGNOSTIC ERROR; DIAGNOSTIC IMAGING; FEMALE; MORTALITY; PATHOLOGY; PREDICTION AND FORECASTING; STANDARD;

BREAST NEOPLASMS; DIAGNOSTIC ERRORS; DIAGNOSTIC IMAGING; FEMALE; HUMANS; PREDICTIVE VALUE OF TESTS; SENTINEL LYMPH NODE BIOPSY;

EID: 0036795150     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(02)00018-5     Document Type: Review

References (210)

1. Breast cancer
2. The new era in breast cancer. Invasion, size, and nodal involvement dramatically decreasing as a result of mammographic screening
3. Breast-conserving therapy vs mastectomy in early-stage breast cancer: a meta-analysis of 10-year survival
4. The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomised trial
5. Risk of internal mammary lymph node metastases and its relevance on prognosis of breast cancer patients
6. Is it useful to remove internal mammary nodes in operable breast cancer?
7. Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol 4). Discriminants for 15-year survival
8. Pathologic findings from the National Surgical Adjuvant Breast Project protocol B-06. 10-year pathologic and clinical prognostic discriminants
9. The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast
10. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer
11. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b trial
12. Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy
13. Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer
14. Is breast-conserving surgery with radiation superior to mastectomy in selected patients?
15. Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer
16. The significance of local control in the primary treatment of breast cancer
17. Assessment of morbidity from complete axillary dissection
18. Impact of axillary lymph node dissection on the therapy of breast cancer patients
19. Incidence of arm swelling following axillary clearance for breast cancer
20. Arm morbidity following treatment of breast cancer with total axillary dissection: a multivariated approach
21. The role of intraoperative lymphatic mapping and sentinel lymphadenectomy in the management of patients with breast cancer
22. The sentinel node in breast cancer-a multicenter validation study
23. Sentinel lymphadenectomy for breast cancer in a community managed care setting
24. Lymphatic mapping and sentinel lymphadenectomy for breast cancer
25. Implementation of new surgical technology: outcome measures for lymphatic mapping of breast carcinoma
26. Credentialing for breast lymphatic mapping: how many cases are enough?
27. Learning sentinel node biopsy: results of a prospective randomized trial of two techniques
28. The impact of prophylactic axillary node dissection on breast cancer survival-a Bayesian meta-analysis
29. Lymph node micrometastases from breast carcinoma: reviewing the dilemma
30. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up
31. Axillary lymph nodes and breast cancer: a review
32. Rationale for routine axillary dissection in carcinoma of the breast
33. Complete axillary lymph node dissection for stage I-II carcinoma of the breast
34. The impact of axillary lymphadenopathy on further treatment in breast cancer? A model for clinical staging
35. Relation of tumor size, lymph node status, and survival in 24 740 breast cancer cases
36. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions
37. Characteristics and treatment of breast cancers 10 mm or less detected by a mammographic screening programme
38. A comparison of axillary node status between cancers detected at the prevalence and first incidence breast screening rounds
39. Incidence and predictors of axillary metastasis in T1 carcinoma of the breast
40. Axillary lymphadenectomy: a diagnostic and therapeutic procedure
41. Axillary lymph node dissection in breast cancer: an evolving question?
42. Breast cancer patients treated without axillary surgery: clinical implications and biologic analysis
43. Is axillary dissection always indicated in invasive breast cancer?
44. Axillary dissection: when and how radical?
45. Ductal carcinoma in situ. Part 2: treatment
46. Surgical treatment of ductal carcinoma in situ of the breast. 10- to 20-year follow-up
47. Mammary ductal carcinoma in situ with microinvasion
48. Breast cancer treatment and natural history: new insights from results of screening
49. Breast cancer: risk of axillary recurrence in node-negative patients following partial dissection of the axilla
50. Axillary dissection in primary surgical treatment of breast cancer: risk of false-negative axillary status
51. A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in patients with breast carcinoma
52. Distribution of axillary node metastases by level of invasion. An analysis of 539 cases
53. Patterns of axillary nodal involvement in breast cancer. Predictability of level one dissection
54. The Edinburgh randomized trial of axillary sampling or clearance after mastectomy
55. Management of early cancer of the breast: report of an international multicentre trial supported by the Cancer Research Campaign
56. Manchester regional breast study-5 and 10 year results
57. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation
58. Simple mastectomy and axillary node sampling (pectoral node biopsy) in the management of primary breast cancer
59. Results of simplified treatment of breast cancer
60. Detection, treatment and outcome of axillary recurrence after axillary clearance for invasive breast cancer
61. Patients with early breast cancer benefit from effective axillary treatment
62. Axillary node dissection in breast cancer
63. Risk of lymphoedema following the treatment of breast cancer
64. Conservative treatment of breast cancer: results of management of axillary lymph node area in 3353 patients
65. Long-term radiation complications following conservative surgery and radiation therapy in patients with early stage breast cancer
66. Edema of the arm as a function of the extent of axillary surgery in patients with stage I-II carcinoma of the breast treated with primary radiotherapy
67. Arm edema in conservatively managed breast cancer: obesity is a major predictive factor
68. The effect of pre- and postmastectomy radiotherapy on the degree of edema, shoulder-joint mobility, and gripping force
69. Quality of life of breast cancer patients with lymphedema
70. The psychological morbidity of breast cancer-related arm swelling
71. Variations in sensitivity after sectioning the intercostobrachial nerve
72. Cellulitis after axillary lymph node dissection for carcinoma of the breast
73. Seroma formation following axillary dissection for breast cancer: risk factors and lack of influence of bovine thrombin
74. Postmastectomy seromas and wound drainage
75. Management of the axilla in operable breast cancer treated by breast conservation: a randomized clinical trial
76. Lymphangiosarcoma in postmastectomy oedema
77. Dynamic MR imaging of invasive breast cancer: correlation with tumour grade and other histological factors
78. Staging of symptomatic primary breast cancer with MR imaging
79. Prediction of axillary lymph node status in invasive breast cancer with dynamic contrast-enhanced MR imaging
80. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET
81. Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability
82. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose
83. Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry
84. Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose PET
85. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer
86. Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose
87. Technetium-99m-sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement
88. 99Tcm-MIBI mammoscintigraphy of breast masses: early and delayed imaging
89. Detection of axillary lymph node metastases in breast carcinoma by technetium-99m sestamibi breast scintigraphy, ultrasound and conventional mammography
90. Technetium-99m sestamibi imaging in the detection of axillary lymph node involvement in patients with breast cancer
91. Technetium-99m-sestamibi uptake in axillary lymph node metastases in breast cancer patients
92. Axillary node metastasis detection in breast cancer with 99mTc- sestaMIBI and 111In-pentetreotide
93. Metastatic axillary lymph node technetium-99m-MIBI imaging in primary breast cancer
94. Thin section computed tomography in the prone position for detection of axillary lymph node metastases in breast cancer
95. CT-pathologic correlation of axillary lymph nodes in breast carcinoma
96. Role of computed tomography in the staging of primary breast cancer
97. Axillary lymph node metastases in breast cancer: preoperative detection with US
98. Ultrasound detection of axillary lymph node metastases in breast cancer
99. Accuracy of ultrasound and clinical examination in the diagnosis of axillary lymph node metastases in breast cancer
100. Role of ultrasonography to detect axillary node involvement in operable breast cancer
101. High resolution sonographic detection of axillary lymph node metastases in breast cancer
102. Value of axillary ultrasonography and sonographically guided puncture of axillary nodes: a prospective study in 144 consecutive patients
103. Multicentre study of ultrasonographically guided axillary node biopsy in patients with breast cancer
104. Ultrasound-guided aspiration biopsy for detection of nonpalpable axillary node metastases in breast cancer patients: new diagnostic method
105. Radioimmunolocalization of primary and metastatic breast cancer
106. Breast cancer imaging with radiolabeled antibodies
107. An approach for the treatment of penile carcinoma
108. Technical details of intraoperative lymphatic mapping for early stage melanoma
109. Lymphatic mapping and sentinel node biopsy in breast cancer
110. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe
111. Intradermal blue dye to identify sentinel lymph-node in breast cancer
112. Intradermal radiocolloid and intraparenchymal blue dye injection optimize sentinel node identification in breast cancer patients
113. Mammary lymphoscintigraphy in breast cancer
114. Sentinel-lymph node biopsy in breast cancer
115. Sentinel lymphadenectomy in breast cancer
116. Complementarity of blue dye and isotope in sentinel node localization for breast cancer: univariate and multivariate analysis of 966 procedures
117. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer
118. Lymphoscintigraphy and feasibility of sentinel node biopsy in 83 patients with primary breast cancer
119. Sentinel axillary lymph node: helpful in axillary management in patients with breast cancer?
120. Identification of axillary sentinel node by lymphotropic dye in breast cancer. Feasibility study apropos of 128 cases
121. Sentinel node localization in patients with breast cancer
122. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection
123. Sentinel lymph node biopsy, an alternative to elective axillary dissection for breast cancer
124. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center
125. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series
126. Lessons learned from 500 cases of lymphatic mapping for breast cancer
127. Identification of the sentinel lymph node in breast cancer: experience from the Institut Curie
128. Initial experience in a community hospital with sentinel lymph node mapping and biopsy for evaluation of axillary lymph node status in palpable invasive breast cancer
129. Tagging sentinel lymph nodes: a study of 100 patients with breast cancer
130. The role of sentinel lymph node biopsy in breast cancer
131. Initial experience with sentinel node biopsy in breast cancer at the National Cancer Center Hospital East
132. Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients
133. Specification of potential indications and contraindications of sentinel lymph node biopsy in breast cancer
134. Biopsy method and excision volume do not affect success rate of subsequent sentinel lymph node dissection in breast cancer
135. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used
136. Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors
137. Lymphatic mapping with intralesional tracer administration in breast carcinoma patients
138. In search of the true sentinel node by different injection techniques in breast cancer patients
139. The true sentinel node by different injection techniques in breast cancer patients
140. Dynamic lymphoscintigraphy to identify the sentinel and satellite nodes
141. Management of the axilla in early breast cancer: is it time to change tack?
142. Limitation in gamma probe localization of the sentinel node in breast cancer patients with large excisional biopsy
143. Particle sizing and biokinetics of interstitial lymphoscintigraphic agents
144. Sentinel node biopsy interpretation: the Milan experience
145. Kinetics of three lymphoscintigraphic agents in patients with cutaneous melanoma
146. Filtered technetium-99m-sulfur colloid evaluated for lymphoscintigraphy
147. Sentinel node staging of early breast cancer using lymphoscintigraphy and the intraoperative gamma-detecting probe
148. Quantitative lymphoscintigraphy I: basic concepts for optimal uptake of radiocolloids in the parasternal lymph nodes of rabbits
149. Radiation dose estimates for interstitial radiocolloid lymphoscintigraphy
150. Radiopharmaceuticals in sentinel lymph-node detection-an overview
151. Gamma probe-guided sentinel node biopsy-optimal timing for injection
152. Sentinel lymph node biopsy in breast cancer: unfiltered radioisotope is superior to filtered
153. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes
154. Sentinel node biopsy in 70 unselected patients with breast cancer: increased feasibility by using 10 mCi radiocolloid in combination with a blue dye tracer
155. Evaluation of mammary lymphoscintigraphy by a single intratumoral injection for sentinel node identification
156. Preoperative lymphoscintigraphy for breast cancer does not improve the ability to identify axillary sentinel lymph nodes
157. Routine preoperative lymphoscintigraphy is not necessary prior to sentinel node biopsy for breast cancer
158. Clinical and histological factors associated with sentinel node identification in breast cancer
159. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer
160. Will the true sentinel node please stand?
161. Pathological investigation of sentinel lymph nodes
162. Consequences of sentinel node in clinical decision making in breast cancer and prospects for future studies
163. Accuracy of intraoperative frozen-section analysis of axillary nodes. Edinburgh Breast Unit team
164. Reliability of intraoperative frozen section and imprint cytological investigation of sentinel lymph nodes in breast cancer
165. Intraoperative assessment of nodal status in the selection of patients with breast cancer for axillary clearance
166. Intraoperative assessment of nodal status in the selection of patients with breast cancer for axillary clearance
167. Touch imprint cytological analysis of sentinel lymph nodes for detecting axillary metastases in patients with breast cancer
168. Use of touch preps for intraoperative diagnosis of sentinel lymph node metastases in breast cancer
169. Intraoperative sentinel lymph node examination by imprint cytology and frozen sectioning during breast surgery
170. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma
171. Sentinel node metastasis in patients with breast carcinoma accurately predicts immunohistochemically detectable nonsentinel node metastasis
172. Implementation of the sentinel node biopsy: a survey among surgeons in the Netherlands
173. Detection and significance of occult metastases in node-negative breast cancer
174. A preliminary report on the usefulness of monoclonal antibodies to CA 15-3 and MCA in the detection of micrometastases in axillary lymph nodes draining primary breast carcinoma
175. Occult metastases in the axillary lymph nodes of patients with breast cancer node negative by clinical and histologic examination and conventional histology
176. Pathologic correlates of prognosis in lymph node-positive breast carcinomas
177. Immunohistochemical detection and significance of axillary lymph node micrometastases in breast carcinoma. A study of 97 cases
178. Occult axillary node metastases in breast cancer: their detection and prognostic significance
179. Occult axillary lymph node metastases in 'node-negative' breast carcinoma
180. Axillary node micrometastases and breast cancer
181. Sentinel lymphadenectomy in breast cancer: identification of sentinel lymph node and detection of metastases
182. Identification of superior markers for polymerase chain reaction detection of breast cancer metastases in sentinel lymph nodes
183. Detection of metastatic breast cancer by beta-hCG polymerase chain reaction
184. Internal mammary node status: a major prognosticator in axillary node-negative breast cancer
185. Long-term follow-up of axillary node-positive breast cancer patients receiving adjuvant systemic therapy alone: patterns of recurrence
186. Internal mammary nodal irradiation in conservatively-managed breast cancer patients: is there a benefit?
187. Radiation safety of the sentinel lymph node technique in breast cancer
188. Guidelines for the safe use of radioactive materials during localization and resection of the sentinel lymph node
189. Radiation protection in radioguided surgery of breast cancer
190. Radiopharmaceuticals for lymphoscintigraphy: including dosimetry and radiation considerations
191. Sentinel lymph node localization in early breast cancer
192. Defining the optimal surgeon experience for breast cancer sentinel lymph node biopsy: a model for implementation of new surgical techniques
193. Sentinel lymph node biopsy as an indicator for axillary dissection in early breast cancer
194. The learning curve for sentinel node biopsy in breast cancer: practical considerations
195. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer
196. Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol No. 4). V. Significance of axillary nodal micro- and macrometastases
197. Detection and significance of occult axillary node metastases in patients with invasive breast cancer
198. Sentinel lymph node biopsy in breast cancer: creating controversy and defining new standards
199. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22
200. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer
201. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16
202. Sentinel node biopsy: a revolution in the surgical management of breast cancer?
203. Audit of a conservative management policy of the axilla in elderly patients with operable breast cancer